These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 24501303)
1. Navigating the challenge of tumor heterogeneity in cancer therapy. Fedele C; Tothill RW; McArthur GA Cancer Discov; 2014 Feb; 4(2):146-8. PubMed ID: 24501303 [TBL] [Abstract][Full Text] [Related]
2. Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. Fan J; Lee HO; Lee S; Ryu DE; Lee S; Xue C; Kim SJ; Kim K; Barkas N; Park PJ; Park WY; Kharchenko PV Genome Res; 2018 Aug; 28(8):1217-1227. PubMed ID: 29898899 [TBL] [Abstract][Full Text] [Related]
3. Zebrafish as a model to assess cancer heterogeneity, progression and relapse. Blackburn JS; Langenau DM Dis Model Mech; 2014 Jul; 7(7):755-62. PubMed ID: 24973745 [TBL] [Abstract][Full Text] [Related]
4. Modeling Tumor Clonal Evolution for Drug Combinations Design. Zhao B; Hemann MT; Lauffenburger DA Trends Cancer; 2016 Mar; 2(3):144-158. PubMed ID: 28435907 [TBL] [Abstract][Full Text] [Related]
5. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution. Kim JY; Gatenby RA Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831 [TBL] [Abstract][Full Text] [Related]
7. Intra-tumor heterogeneity from a cancer stem cell perspective. Prasetyanti PR; Medema JP Mol Cancer; 2017 Feb; 16(1):41. PubMed ID: 28209166 [TBL] [Abstract][Full Text] [Related]
8. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS. Verkhivker GM Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral Heterogeneity: More Than Just Mutations. Hinohara K; Polyak K Trends Cell Biol; 2019 Jul; 29(7):569-579. PubMed ID: 30987806 [TBL] [Abstract][Full Text] [Related]
10. Cancer systems biology in the genome sequencing era: part 2, evolutionary dynamics of tumor clonal networks and drug resistance. Wang E; Zou J; Zaman N; Beitel LK; Trifiro M; Paliouras M Semin Cancer Biol; 2013 Aug; 23(4):286-92. PubMed ID: 23792107 [TBL] [Abstract][Full Text] [Related]
11. Chung WJ; Daemen A; Cheng JH; Long JE; Cooper JE; Wang BE; Tran C; Singh M; Gnad F; Modrusan Z; Foreman O; Junttila MR Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10947-E10955. PubMed ID: 29203670 [No Abstract] [Full Text] [Related]
12. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Zhao B; Pritchard JR; Lauffenburger DA; Hemann MT Cancer Discov; 2014 Feb; 4(2):166-74. PubMed ID: 24318931 [TBL] [Abstract][Full Text] [Related]
13. Systems heterogeneity: An integrative way to understand cancer heterogeneity. Wang DC; Wang X Semin Cell Dev Biol; 2017 Apr; 64():1-4. PubMed ID: 27552921 [TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. Zhai Z; Yu X; Yang B; Zhang Y; Zhang L; Li X; Sun H Semin Cell Dev Biol; 2017 Apr; 64():107-115. PubMed ID: 27578007 [TBL] [Abstract][Full Text] [Related]
15. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy. Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278 [TBL] [Abstract][Full Text] [Related]
16. Intravital Insights into Heterogeneity, Metastasis, and Therapy Responses. Scheele CLGJ; Maynard C; van Rheenen J Trends Cancer; 2016 Apr; 2(4):205-216. PubMed ID: 28741572 [TBL] [Abstract][Full Text] [Related]